CymaBay Therapeutics (CBAY) Announces Earnings Results

CymaBay Therapeutics (NASDAQ:CBAY) posted its quarterly earnings results on Thursday, March 15th. The biopharmaceutical company reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.06, Bloomberg Earnings reports. The business had revenue of $5.20 million for the quarter, compared to the consensus estimate of $1.25 million.

Shares of NASDAQ CBAY traded down $0.16 during midday trading on Friday, reaching $11.10. 582,827 shares of the company were exchanged, compared to its average volume of 1,048,034. The stock has a market cap of $658.73, a PE ratio of -14.05 and a beta of 2.06. CymaBay Therapeutics has a one year low of $3.16 and a one year high of $15.59. The company has a debt-to-equity ratio of 0.04, a quick ratio of 6.35 and a current ratio of 6.35.

How to Become a New Pot Stock Millionaire

In related news, Director Kurt Von Emster sold 218,057 shares of the business’s stock in a transaction on Wednesday, February 14th. The shares were sold at an average price of $15.89, for a total value of $3,464,925.73. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Carl Goldfischer sold 15,000 shares of the business’s stock in a transaction on Thursday, March 22nd. The stock was sold at an average price of $13.03, for a total transaction of $195,450.00. Following the completion of the sale, the director now directly owns 9,340 shares in the company, valued at approximately $121,700.20. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 815,648 shares of company stock worth $10,283,751. Insiders own 15.10% of the company’s stock.

A number of research firms have recently weighed in on CBAY. Piper Jaffray reiterated a “buy” rating and issued a $16.00 price target on shares of CymaBay Therapeutics in a research report on Friday, March 16th. Cantor Fitzgerald reiterated a “buy” rating and issued a $16.00 price target on shares of CymaBay Therapeutics in a research report on Friday, March 16th. BidaskClub downgraded shares of CymaBay Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, March 15th. Oppenheimer set a $18.00 price target on shares of CymaBay Therapeutics and gave the company a “buy” rating in a research report on Monday, March 12th. Finally, Roth Capital reiterated a “buy” rating and issued a $27.00 price target on shares of CymaBay Therapeutics in a research report on Thursday, January 25th. One analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the stock. CymaBay Therapeutics has a consensus rating of “Buy” and an average price target of $17.78.

ILLEGAL ACTIVITY WARNING: “CymaBay Therapeutics (CBAY) Announces Earnings Results” was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this story on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be viewed at https://www.dispatchtribunal.com/2018/04/07/cymabay-therapeutics-cbay-announces-earnings-results-beats-estimates-by-0-02-eps.html.

CymaBay Therapeutics Company Profile

Cymabay Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to treat specialty and orphan diseases. It engages in developing seladelpar (MBX-8025), a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase 2 clinical study for the treatment of primary biliary cholangitis and homozygous familial hypercholesterolemia; and arhalofenate, which completed five Phase II clinical trials for the treatment of gout.

Earnings History for CymaBay Therapeutics (NASDAQ:CBAY)

Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply